There are currently 951 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama-Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
NCT04523727
Recruiting
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 6 years and 16 years
Trial Updated:
04/15/2025
Locations: University of Alabama at Birmingham (UAB) - Children's of Alabama, Birmingham, Alabama
Conditions: Hyperphosphatemia Related to Chronic Kidney Disease
Register for Updates
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690
Recruiting
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Retina Consultants of Alabama, Birmingham, Alabama
Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Register for Updates
Telehealth Delivered Home-based Walking for Vets With Peripheral Artery Disease
NCT06033924
Recruiting
Walking is beneficial for adults with peripheral arterial disease. Benefits include the ability to walk for longer periods and general well being (quality of life). This study will look at two types of delivery methods for a home-based walking program. The walking program includes step count goals, information on healthy walking and motivational messages. The two delivery methods include a web-based delivery and an telehealth delivery. Participants are randomized to either one of the delivery me... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/15/2025
Locations: Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama
Conditions: Peripheral Artery Disease
Register for Updates
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
NCT06265584
Recruiting
In an effort to reduce graft versus host disease (GVHD) and enhance graft versus leukemia (GVL) effect post allogenic hematopoietic stem cell transplantation (AHSCT), recent research has focused on host immune cell depletion. Frame shifting anti-thymocyte globulin (ATG) backwards to earlier days before days 0 can result in deeper host and less graft T-cell depletion, leading to better immune reconstitution. Preliminary data where 80% of the ATG dose is given on days -6,-5,-4 and 20% given on day... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
Register for Updates
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076
Recruiting
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Total Dermatology, Birmingham, Alabama +1 locations
Conditions: Plaque Psoriasis
Register for Updates
ACT for HIV-Positive Men
NCT06625437
Recruiting
The purpose of the current study is to examine the feasibility and effectiveness of acceptance and commitment therapy, a specific form of cognitive-behavioral therapy, for treating general mental health concerns among HIV-positive men.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Stress, Anxiety, Mental Disorder, Distress-based Psychopathology
Register for Updates
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016
Recruiting
The Sponsor is developing a progestin-only contraceptive transdermal system (patch). The main purpose of this study is to look at how safe the study patch is and how well it works in preventing pregnancy. The study will also look at how well the study patch is tolerated. The study patch is a transdermal system that contains the active ingredient, progestin.
Gender:
FEMALE
Ages:
16 years and above
Trial Updated:
04/15/2025
Locations: Alabama Clinical Therapeutics, LLC, Birmingham, Alabama
Conditions: Female Contraception
Register for Updates
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
NCT06857006
Recruiting
Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/15/2025
Locations: University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center, Birmingham, Alabama
Conditions: Brain Metastases
Register for Updates
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
NCT05404750
Recruiting
People living with HIV (PLWH) who use drugs experience significant health disparities including lower rates of retention in HIV care and higher rates of unsuppressed viral load, resulting in secondary infections and increased mortality. The proposed study will used mixed methods to explore (a) the relationship between healthcare providers' attitudes towards working with PLWH who use drugs and providers' acceptance and practice of structural and relational harm reduction; (b) the degree to which... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Human Immunodeficiency Virus, Substance Use, Stigma, Social
Register for Updates
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
NCT05434689
Recruiting
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administrat... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Multiple Myeloma
Register for Updates
Sensory Filtering in the Human Basal Ganglia as a Mechanism of Parkinson's Disease
NCT05482126
Recruiting
The investigators are investigating the brain activity associated with sensory information in movement disorders in order to improve treatment of these symptoms beyond what is currently available.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/14/2025
Locations: The University of Alabama at Birmingham Hospital, Birmingham, Alabama
Conditions: Parkinson Disease
Register for Updates
PREVENT ALL ALS Study
NCT06581861
Recruiting
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates